S-1: OS Therapies Files S-1 for Resale of Shares Following Positive Phase IIb Trial Results and Strategic Asset Acquisition

OS Therapies Incorporated has filed an S-1 registration statement to allow selling stockholders to resell up to 7.5 million shares, following positive Phase IIb clinical trial results for its lead Osteosarcoma drug candidate, OST-HER2, and the strategic acquisition of new immune-oncology assets.

Summary

• OS Therapies Incorporated is a clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma (OS) and other solid tumors, particularly addressing the unmet need for new therapies in bone cancers affecting children and young adults.
• The company's lead product candidate, OST-HER2 (OST31-164), a cancer immunotherapy, achieved its primary endpoint with statistical significance in a Phase IIb clinical trial for recurrent Osteosarcoma, with full enrollment of 41 patients completed in October 2023.
• Trial results showed 33% event-free (recurrence-free) survival at 12 months for OST-HER2 treated patients, compared to 20% in the best available historical control group.
• Overall survival rates for OST-HER2 treated patients were 91% at 12 months (vs. 80% in control) and 61% at 24 months (vs. 40% in control), with a favorable safety profile and no treatment-emergent adverse events classified as CTCAE Grade 5 (death).
• The company plans to request a Type B or Type C FDA meeting in the second quarter of 2025 to discuss the data and the path to a Biologics License Application (BLA), with submission planned shortly thereafter.
• OS Therapies also owns rights to the OST-Tunable Drug Conjugate (OST-tADC) platform, a next-generation antibody-drug conjugate (ADC) technology, currently in preclinical development, with a lead program targeting folate receptor alpha for ovarian and endometrial cancers.
• The company completed a Private Placement in December 2024 and January 2025, raising approximately $7,103,000 in gross proceeds through the issuance of Series A Preferred Stock and warrants.
• On April 9, 2025, OS Therapies completed the acquisition of HER2 and Lm-related immune-oncology assets from Ayala Pharmaceuticals, Inc. for an aggregate purchase price of $8,000,000, consisting of $500,000 in cash and $7,500,000 worth of common stock (4,774,637 shares).

Sentiment

Score: 7

Explanation: The document presents strong positive clinical trial results for the company's lead product and strategic acquisitions that expand its pipeline, indicating significant progress and future potential. However, the auditor's 'going concern' explanatory paragraph introduces a notable financial risk, tempering the overall positive sentiment.

Positives

• The lead product candidate, OST-HER2, achieved its primary endpoint with statistical significance in a Phase IIb clinical trial for recurrent Osteosarcoma, demonstrating improved event-free and overall survival rates compared to historical controls.
• OST-HER2 exhibited a favorable safety profile in the Phase IIb trial, with no treatment-emergent adverse events classified as CTCAE Grade 5 (death), supporting its potential for regulatory approval.
• OST-HER2 has received Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation from the FDA, which may provide certain regulatory advantages and market exclusivity.
• The strategic acquisition of HER2 and Lm-related immune-oncology assets from Ayala Pharmaceuticals, Inc. expands the company's pipeline with two investigational new drug (IND) filings for non-small cell lung cancer and prostate cancer.
• The company successfully completed a Private Placement, raising approximately $7.1 million in gross proceeds, strengthening its financial position.
• The company possesses a second promising technology platform, OST-tADC, a next-generation tunable antibody-drug conjugate (ADC) with a plug-and-play system, currently in preclinical development for various solid tumors.

Negatives

• The auditor's report contains an explanatory paragraph regarding the Company's ability to continue as a going concern, indicating substantial doubt about its ability to meet future obligations without additional funding.
• The current S-1 filing is primarily for the resale of shares by existing stockholders, meaning the company will not receive direct proceeds from these sales, except from the cash exercise of certain warrants.

Risks

• The company's ability to continue as a going concern is subject to significant doubt, as highlighted by the auditor's explanatory paragraph.
• Investing in the company's shares is highly speculative and involves a high degree of risk, as stated in the prospectus.
• There is uncertainty regarding whether a Phase III clinical trial will be necessary for the advancement of OST-HER2 through the regulatory approval process, which could delay or increase the cost of approval.
• The conditional USDA license for OST-HER2 for canine Osteosarcoma was allowed to lapse, and obtaining a new license requires contracting with a suitable USDA licensed contract manufacturer and submitting additional data.
• Further preclinical trials are required for the OST-tADC product candidate prior to the submission of an IND to pursue human clinical trials, which involves significant time and expense.

Future Outlook

The company plans to request a Type B or Type C FDA meeting in the second quarter of 2025 to discuss the data from its Phase IIb clinical trial for OST-HER2 and the path to a Biologics License Application (BLA), with submission planned shortly thereafter. Subject to regulatory approval, OS Therapies intends to evaluate OST-HER2's potential use, alone and in combination with HER2 targeting antibodies, in other solid tumors including breast, esophageal, and lung cancers. Additionally, the company aims to conclude preclinical and toxicology trials for its OST-tADC platform's lead drug candidate and file for an Investigational New Drug (IND) application to initiate a Phase I trial in ovarian cancer and other folate receptor alpha overexpressing cancers. The company also plans to establish global commercial and medical affairs capabilities for OST-HER2 based therapies and seek a new conditional USDA license for OST-HER2 for canine use.

Management Comments

• "We believe the efficacy results, combined with the favorable safety profile and the unmet clinical need, support the potential for regulatory approval."

Industry Context

OS Therapies operates in the highly specialized and competitive biopharmaceutical sector, focusing on oncology, particularly rare cancers like Osteosarcoma, which has seen no new FDA-approved treatments for over 40 years. This positions the company to address a significant unmet medical need. The company's development of an Antibody-Drug Conjugate (ADC) platform (OST-tADC) aligns with a growing industry trend, as large pharmaceutical firms show increased acquisition and licensing interest in ADC technology due to its potential to capture a significant share of the global cancer market and its compatibility with other cancer agents like immunotherapies.

Comparison to Industry Standards

• The company highlights that "No new treatments have been approved by the U.S. Food and Drug Administration (FDA) for human Osteosarcoma for more than 40 years," underscoring the significant unmet need its lead candidate addresses.
• OS Therapies states, "We are not aware of any competing adjuvant therapy for Osteosarcoma to be tested in children that is further along in the development process than OST-HER2," suggesting a potential first-mover advantage in this specific pediatric indication.
• The Phase IIb clinical trial results for OST-HER2 were evaluated against "the best available historical control group from U.S. published literature," providing a benchmark for efficacy comparison.
• The preclinical animal study for ADXS-HER2 (predecessor to OST-HER2) in canines was compared to a "historical control group with Human Epidermal Growth Factor Receptor 2-positive (HER2) appendicular Osteosarcoma, a well-recognized spontaneous model for pediatric Osteosarcoma," demonstrating the translational relevance of the findings for human Osteosarcoma.

Corporate Governance

Related Party Transactions

• The company issued a convertible note with a principal amount of $2,400,000 to BlinkBio, Inc., a related party (due to a former Chairman's affiliation), in exchange for a license agreement to utilize silicon-based drug conjugates and methods.
• On March 15, 2021, the company issued 1,302,082 shares of Series A preferred stock to BlinkBio in exchange for the aforementioned convertible note.

Stakeholder Impact

• **Shareholders**: Potential for significant value appreciation due to positive clinical trial results and expanded pipeline, but also face risks of dilution from warrant exercises and future capital raises, and the inherent financial risk indicated by the 'going concern' warning.
• **Patients**: Stand to benefit from the potential development and commercialization of new, much-needed treatment options for Osteosarcoma and other solid tumors, particularly for pediatric and young adult populations.
• **Employees**: Benefit from continued employment and potential growth opportunities within a company making significant strides in drug development, though the 'going concern' issue introduces uncertainty.
• **Creditors**: Are impacted by the company's financial health and its ability to continue operations, as indicated by the 'going concern' explanatory paragraph, which may affect their ability to recover debts.

Next Steps

• Request a Type B or Type C FDA meeting in the second quarter of 2025 to discuss the data from the Phase IIb clinical trial for OST-HER2 and the path to a Biologics License Application (BLA).
• Submit a Biologics License Application (BLA) with the FDA CBER for approval to market OST-HER2 shortly after positive FDA feedback.
• Evaluate OST-HER2's potential use, both alone and in combination with HER2 targeting antibodies, in other solid tumors including breast, esophageal, and lung cancers.
• Conclude preclinical and toxicology trials with the lead drug candidate for OST-tADC (OST-tADC-A, Exatecan-silanol-FRa).
• File for an Investigational New Drug (IND) application to initiate a Phase I trial for OST-tADC in ovarian cancer and other folate receptor alpha overexpressing cancers.
• Establish global commercial and medical affairs capabilities for OST-HER2 based therapies.
• Request a new conditional license from USDA for OST-HER2 for veterinary use in canines once a suitable USDA licensed contract manufacturer is contracted.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Osteosarcoma, Cancer Immunotherapy, HER2, Solid Tumors, Clinical Stage, Oncology, Antibody-Drug Conjugate, ADC, Rare Disease, Orphan Drug, FDA Approval, BLA, Private Placement, Asset Acquisition, NYSE American